# HIG-Syn: a hypergraph and interaction-aware multigranularity network for predicting synergistic drug combinations

**Authors:** Yuexi Gu, Jian Zu, Yongheng Sun, Louxin Zhang

PMC · DOI: 10.1093/bioinformatics/btaf215 · 2025-07-15

## TL;DR

This paper introduces HIG-Syn, a new deep learning model that improves predictions of drug combinations that work well together.

## Contribution

HIG-Syn integrates hypergraph and interaction-aware modules to better capture biological interactions for drug synergy prediction.

## Key findings

- HIG-Syn outperforms existing machine learning models in predicting drug synergy.
- Five of the predicted drug combinations are supported by experimental evidence in the literature.

## Abstract

Drug combinations can not only enhance drug efficacy but also effectively reduce toxic side effects and mitigate drug resistance. With the advancement of drug combination screening technologies, large amounts of data have been generated. The availability of large data enables researchers to develop deep learning methods for predicting drug targets for synergistic combination. However, these methods still lack sufficient accuracy for practical use, and most overlook the biological significance of their models.

We propose the HIG-Syn (hypergraph and interaction-aware multigranularity network for drug synergy prediction) model, which integrates a coarse-granularity module and a fine-granularity module to predict drug combination synergy. The former utilizes a hypergraph to capture global features, while the latter employs interaction-aware attention to simulate biological processes by modeling substructure–substructure and substructure–cell line interactions. HIG-Syn outperforms state-of-the-art machine learning models on our validation datasets extracted from the DrugComb and GDSC2 databases. Furthermore, the fact that five of the 12 novel synergistic drug combinations predicted by HIG-Syn are strongly supported by experimental evidence in the literature underscores its practical potential.

The source code is available at https://github.com/gracygyx/HIGSyn

## Full-text entities

- **Genes:** TOP2A (DNA topoisomerase II alpha) [NCBI Gene 7153] {aka TOP2, TOP2alpha, TOPIIA, TP2A}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, BCL2L1 (BCL2 like 1) [NCBI Gene 598] {aka BCL-XL/S, BCL2L, BCLX, Bcl-X, PPP1R52}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, SYNM (synemin) [NCBI Gene 23336] {aka DMN, SYN}, WEE1 (WEE1 G2 checkpoint kinase) [NCBI Gene 7465] {aka WEE1A, WEE1hu}, H2AX (H2A.X variant histone) [NCBI Gene 3014] {aka H2A.X, H2A/X, H2AFX}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, SLTM (SAFB like transcription modulator) [NCBI Gene 79811] {aka Met}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, JAK2 (Janus kinase 2) [NCBI Gene 3717] {aka JTK10}, CCND1 (cyclin D1) [NCBI Gene 595] {aka BCL1, D11S287E, PRAD1, U21B31}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, MET (MET proto-oncogene, receptor tyrosine kinase) [NCBI Gene 4233] {aka AUTS9, DA11, DFNB97, HGFR, RCCP2, c-Met}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, ATR (ATR checkpoint kinase) [NCBI Gene 545] {aka FCTCS, FRP1, MEC1, SCKL, SCKL1}
- **Diseases:** colon cancer (MESH:D015179), acute lymphoblastic leukemia (MESH:D054198), cytotoxic (MESH:D064420), triple-negative (MESH:D064726), breast cancer (MESH:D001943), ovarian cancer (MESH:D010051), HIV (MESH:D015658), glioblastoma (MESH:D005909), melanoma (MESH:D008545), cancer (MESH:D009369), DL (MESH:D007859), myelofibrosis (MESH:D055728), non-Mendelian diseases (MESH:D000073296), nonsmall cell lung cancer (MESH:D002289), colon adenocarcinoma (MESH:D003110)
- **Chemicals:** GAT (-), Doxorubicin (MESH:D004317), Pyridine (MESH:C023666), Carboplatin (MESH:D016190), Etoposide (MESH:D005047), AZD4320 (MESH:C000720448), Erlotinib (MESH:D000069347), AZD1775 (MESH:C549567), 1,25-dihydroxy vitamin D3 (MESH:D002117), hydrogen (MESH:D006859), AZD5991 (MESH:C000629704), azepine (MESH:D001381), reactive oxygen species (MESH:D017382), AZD6738 (MESH:C000611951), Vismodegib (MESH:C538724), Dactolisib (MESH:C531198), vitamin D (MESH:D014807), Paclitaxel (MESH:D017239), Vincristine (MESH:D014750), amide (MESH:D000577), 5-FU (MESH:D005472), benzene (MESH:D001554), Ruxolitinib (MESH:C540383), Taselisib (MESH:C582924), Crizotinib (MESH:D000077547), Navitoclax (MESH:C528561)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** GDSC2 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_A628), EML4- — Mus musculus (Mouse), Factor-dependent cell line (CVCL_9107), T-47D — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0553), HT-29 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0320), SK-OV-3 — Homo sapiens (Human), Ovarian serous cystadenocarcinoma, Cancer cell line (CVCL_0532), MHH-ES-1 — Homo sapiens (Human), Ewing sarcoma, Cancer cell line (CVCL_1411), NCI-60 — Homo sapiens (Human), Lung small cell carcinoma, Cancer cell line (CVCL_A592), C32 — Homo sapiens (Human), Amelanotic melanoma, Cancer cell line (CVCL_1097)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12261487/full.md

---
Source: https://tomesphere.com/paper/PMC12261487